MeSH tree: C04.588.894.797.520.109
The onset and aggressiveness of cancer are related to the abnormal behavior of certain genes, known as oncogenes. The best-known of these alterations is mutation, but it is not the only one. Sometimes, within a cell, a very ...
Feb 6, 2026
0
8
University of Queensland researchers who mapped cancer cell "neighborhoods" in the most common type of lung cancer have found cell metabolism plays a critical role in determining how lung cancer patients will respond to immunotherapy. ...
Feb 3, 2026
0
7
Patients with advanced lung cancer who received immunochemotherapy before 15:00 (3 p.m.) had a more delayed disease progression than patients receiving treatment later in the day. The findings, published as part of a randomized ...
Feb 2, 2026
0
39
Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node evaluation is needed during surgery for non-small cell lung cancer (NSCLC) to accurately identify cancer ...
Jan 31, 2026
0
6
Following the 2018 federal expansion of short-term limited-duration (STLD) insurance plans, limited or no state regulation of plans was associated with decreases in timely cancer treatment initiation, according to a study ...
Jan 29, 2026
0
7
When lung cancer treatment stops working, what happens next? New research reveals the answer may depend on how the cancer grows.
Jan 22, 2026
0
10
A recent study has analyzed the relationship between different air pollutants and the main subtypes of lung cancer.
Jan 21, 2026
0
10
A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a first-in-class chemical inhibitor that precisely and selectively targets the ATAC complex, a critical cellular ...
Jan 19, 2026
0
44
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting ...
Jan 14, 2026
0
10
A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living with small cell lung cancer (SCLC). However, its cost raises questions about sustainability, prevention ...
Jan 12, 2026
0
15
